AstraZeneca (AZ) has shrugged off a “significant... revolt”, says Ian Johnston in the Financial Times. Shareholders approved a potential £1.8m pay rise for CEO Pascal Soriot, but more than a third of them voted against a package advisers had called “excessive”. Critics had argued that Soriot was already one of the best-paid CEOs in the blue-chip index; he received £16.9m last year.
His supporters insisted that he was “massively underpaid” given the performance of the business under his watch. AstraZeneca also argued that the raise was needed in order “to be competitive in the global market for talent”, especially in relation to the US.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It has also “successfully launched a series of next-generation oncology medicines, partnered with Oxford University in bringing out a Covid vaccine in record time and built a research and development campus in Cambridge employing 2,300 scientists”. What’s more, given that demand for top executives is “intensely mobile”, the city’s “top talent must be fully incentivised to stay put”.
US pay is out of control
It’s true that AZ’s top team could be poached by US rivals offering “greater fistfuls of dollars”, says Nils Pratley in The Guardian. Still, just because US executives’ pay is “wild, and becoming wilder by European standards”, doesn’t mean that UK companies should follow suit, especially since the idea that the two markets are comparable is “selfserving nonsense” in many cases.
Many FTSE firms already “take their owners for fools”, especially Centrica, which “somehow thinks £8.2m for its chief executive Chris O’Shea was an acceptable outcome last year”. The issue isn’t going away, says Oliver Shah in The Sunday Times. This is shaping up to be a “landmark annual meeting season for corporate pay”, as years of “boardroom grumbling” over the differential with the US and private equity have “led to action by a few plucky pioneers”.
Both the London Stock Exchange Group and Smith & Nephew want to hike the amount that their CEOs can receive. While there are plenty of “mediocre” CEOs “who very much don’t need a pay rise”, there is evidence that in some cases “one-size-fits-all solutions” are “holding back” the biggest companies.
On balance, the “grumbling” about Soriot’s pay may have been misguided, as he is “probably worth it” given the “astonishing returns” he has delivered, says Alex Brummer in the Daily Mail. Still, the kerfuffle means that shareholders will benefit too. Hours before the vote AstraZeneca threw in an extra “sweetener” to persuade them to approve the package: a 7% increase in the dividend this year.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Autumn Budget tax changes: how is your generation affected?The chancellor expects everyone to do their bit to boost the nation's finances but the tax burden is by no means shared equally
-
Revealed: pension savers ditch investment trusts and favour passive fundsDemand for investment trusts is cooling among self-invested personal pension (Sipp) customers, who are increasingly choosing money market funds, passive funds and individual shares
-
Leading European companies offer long-term growth prospectsOpinion Alexander Darwall, lead portfolio manager, European Opportunities Trust, picks three European companies where he'd put his money
-
How to harness the power of dividendsDividends went out of style in the pandemic. It’s great to see them back, says Rupert Hargreaves
-
Why Trustpilot is a stock to watch for exposure to the e-commerce marketTrustpilot has built a defensible position in one of the most critical areas of the internet: the infrastructure of trust, says Jamie Ward
-
Tetragon Financial: An exotic investment trust producing stellar returnsTetragon Financial has performed very well, but it won't appeal to most investors – there are clear reasons for the huge discount, says Rupert Hargreaves
-
How to capitalise on the pessimism around Britain's stock marketOpinion There was little in the Budget to prop up Britain's stock market, but opportunities are hiding in plain sight. Investors should take advantage while they can
-
London claims victory in the Brexit warsOpinion JPMorgan Chase's decision to build a new headquarters in London is a huge vote of confidence and a sign that the City will remain Europe's key financial hub
-
The consequences of the Autumn Budget – and what it means for the UK economyOpinion A directionless and floundering government has ducked the hard choices at the Autumn Budget, says Simon Wilson
-
Reinventing the high street – how to invest in the retailers driving the changeThe high street brands that can make shopping and leisure an enjoyable experience will thrive, says Maryam Cockar
